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Complications of TAVR From an Anesthesia
Perspective
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Transcatheter aortic valve replacement (TAVR) has become the predominant technique
for aortic valve replacement in the United States. Initially approved for high surgical risk
patients, TAVR is now approved for most patients requiring valve therapy, including younger, lower-risk patients. The procedure is ideally performed in a hybrid operating room
equipped with fluoroscopic equipment and transesophageal echocardiogram (TEE) imaging
that can be viewed simultaneously by the operating team. The operating room should also
be equipped to allow initiation of cardiopulmonary bypass, if necessary. Cardiac anesthesia teams are often involved with the management of these patients. This mini-review is
designed to summarize potential complications that anesthesiologists may contend with
during TAVR.
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Introduction

Every year, over 70 000 patients undergo transcatheter aortic valve replacement
(TAVR).1 TAVR is performed in all 50 United
States, more frequently than surgical aortic
valve replacements (approximately 57 000 in
2019).1 Most TAVR procedures are performed
with a transfemoral technique, during which
large-bore catheters or sheaths are placed
via the common femoral artery. The crimped
valve and delivery system are then passed in a
retrograde fashion via the iliofemoral arteries
and the aorta to engage the native aortic valve.
Patients are evaluated for the appropriateness
of this approach using multi-dimensional CT
scanning (TAVR CTA), which also allows sizing
of the aortic annulus and appropriate valve
size selection.3 If the TAVR CTA is inadequate
or there are concerns about contrast exposure,
such as renal insufficiency, a 3D transesophageal echocardiogram (TEE) is used to confirm

the annular area for sizing the prosthesis. A
minority of patients require alternative access
such as transaxillary, transcarotid, transaortic,
transsubclavian, or transapical approaches.4 At
our center, any alternative access TAVR procedure is done with general anesthesia and
endotracheal intubation. Most transfemoral
cases at our institution are performed with
monitored anesthesia care, or a so-called “minimalist approach.” The purported advantage of
a minimalist approach is faster recovery and
earlier discharge from the hospital.5 Therefore,
one of the first responsibilities of the anesthesia team is to assess the appropriateness of
the patient for monitored anesthesia care vs.
general anesthesia. Patients who will require
TEE, have difficulty lying supine, high anxiety
states, or impaired cardiopulmonary function
may benefit from a general anesthetic.

www.hcahealthcarejournal.com
© 2022 HCA Physician Services, Inc. d/b/a
Emerald Medical Education

HCA Healthcare
Journal of Medicine

225

HCA Healthcare Journal of Medicine

Intraoperative and Postoperative
Considerations

There are technical differences between types
of transcatheter valves. A balloon-expandable
valve, such as the Edwards S3 Ultra device, is
positioned within the aortic annulus and then
deployed by balloon expansion during a rapid
pacing sequence (typically 180 beats per minute), which markedly reduces cardiac output
and systolic pressure, to ensure safe and accurate deployment.6 Self-expanding transcatheter valves, such as the Medtronic Evolut Proplus device, are more slowly deployed, often
using measured cardiac pacing at a slower rate
(90-120 beats per minute) to modestly reduce
the blood pressure until annular contact of
the stent frame is made and the transcatheter
valve is sufficiently deployed to allow opening and restoration of transvalvular flow and
systolic blood pressure.7 Thus, the anesthesia
team should be prepared with vasopressors
and dilators drawn up and ready for immediate
use to treat persistent hypotension, or rebound
hypertension, after deployment of the valve.
For patients undergoing TAVR with markedly
reduced left ventricular systolic function, it may
be prudent to have epinephrine drawn up and
on the field, for the implanting physicians to
administer directly into the aorta This is only
done if the patient is refractory to conventional
intravenous resuscitation with vasopressors.8
Other complications that may occur during
TAVR include:

Respiratory Complications

Hypoventilation due to sedation, and subsequent respiratory acidosis, can be problematic
and contribute to hemodynamic instability
during valve deployment.9 Our facility no longer
obtains pulmonary function tests as part of our
pre-operative testing for TAVR, but an awareness of underlying lung disease and obstructive
sleep apnea is essential. Vigilance is required
in elderly patients who may be more sensitive
to the effects of prolonged sedation. As with
other surgeries performed under moderate
or deep sedation, anesthesia providers should
be prepared for advanced airway management
and conversion to general anesthesia.

Arrhythmias

Bradycardia and heart block may occur immediately after valve deployment. A temporary right
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ventricular pacing wire is usually in place for a
TAVR procedure, to perform rescue pacing if
necessary, but some valve teams pace via the
left ventricular guide wire.9 Preoperative ECG
should be reviewed for pre-existing bundle
branch block or bradyarrhythmia to determine
if a patient is at increased risk of bradyarrhythmia after valve deployment. For those patients,
a temporary pacing lead can be placed via the
internal jugular vein so that leads can be left in
place for 24-hour monitoring without confining
the patient to bed rest, as would be required
with a trans-femoral pacing lead. A small percentage of patients develop heart block greater
than 24 hours after the procedure, including
some who are already discharged from the hospital.10 Post-anesthesia care unit staff should
be made aware of the increased risk of postoperative arrhythmias.
Tachyarrhythmias may occur during TAVR procedures. The most common tachyarrhythmia
is atrial fibrillation or atrial flutter. Treatment
with antiarrhythmic drugs should be judicious
and discussed with the heart team, given the
previously described risk of heart block. Ventricular tachycardia or ventricular fibrillation
is rare, but defibrillation pads are routinely
placed. Treatment by advanced cardiac life support protocol is recommended.11

Bleeding

A variety of techniques are used to control
bleeding from the femoral access sites.12 Closure devices are common and may be imperfect with regard to controlling bleeding
from access sites.12 Blood loss can usually be
controlled by direct pressure but occasionally
requires endovascular or open surgical treatment. Reversal of heparin is contraindicated
while endovascular devices are being used. If
the case is complicated by a major bleed and
the valve has been deployed, endovascular
devices can be removed and protamine can be
promptly administered. Occult retro-peritoneal
bleeding from iliac rupture can present with
insidious hypotension. The anesthesia team
should be monitoring for hypotension and have
the ability to trend hemoglobin and hematocrit
levels. Equipment for blood product transfusion should be readily available.
A rare complication is myocardial perforation,
from either right ventricular or left ventricular
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devices.13 Myocardial perforation can manifest
as pericardial effusion and tamponade resulting
in low cardiac output and hypotension. When a
minimalist approach is being used, the patient
does not have a TEE probe in place and the
presence of tamponade may be diagnosed by
rising central venous pressure or jugular vein
distension, hypotension, a widened cardiac silhouette on fluoroscopy, or transthoracic echocardiography. The heart team is able to drain
the pericardium and relieve tamponade with
either a catheter or an incision, which may not
immediately stop the bleeding. If a Cell Saver is
available, heterologous blood transfusion may
be minimized.
Annular rupture may also result in pericardial
tamponade and cardiogenic shock.14 Treatment
would require emergency open heart surgery
and the anesthesia team should be prepared
with an endotracheal tube, appropriate venous
access, and medications to facilitate surgery.

Femoral Artery Occlusion and Limb
Ischemia

Occasionally, the common femoral artery becomes obstructed after the sheath is removed,
due to trauma to the intima or dissection of
the vessel. The heart team would typically treat
the obstruction with endovascular techniques.
There may be a subsequent period of ischemia
reperfusion, resulting in metabolic acidosis and
electrolyte disturbance. The anesthesia team
should be prepared to monitor arterial blood
gases, point-of-care electrolytes, and anticoagulation as the heart team works to restore limb
perfusion.

Coronary Artery Obstruction

Although careful measurements of valve stent
height, sino-tubular junction height, sinus of
Valsalva diameter, leaflet calcification, and
coronary artery heights are made in the TAVR
planning stages, there may be unexpected
coronary artery obstruction after valve deployment.15 This obstruction can result in acute
myocardial ischemia, myocardial dysfunction,
and cardiogenic shock. The anesthesia team
must be prepared with inotropes, antiarrhythmic medications, and potential preparations
for cardiopulmonary bypass. The heart team
can avoid this complication with careful preoperative planning, pre-placement of a cor-

onary stent (“parked” in the coronary artery,
but not deployed), or 70% deployment of a
self-expanding valve. At that point, aortic root
angiography can help determine if a coronary
obstruction will occur. The self-expanding valve
can be recaptured and removed if a coronary
obstruction appears likely to occur.

Misplaced Heart Valve

A transcatheter valve can be deployed in a way
that creates severe aortic valve insufficiency.16
Obstruction of the left ventricular outflow
tract is extremely unlikely. Valvular insufficiency
may be treated by secondary balloon dilation,
to further expand the valve, or by the placement of another transcatheter heart valve. If
the patient is hemodynamically unstable due to
severe, acute, aortic regurgitation, the anesthesia team should be prepared to support
the patient with appropriate inotropic therapy.
Valves that embolize may become lodged in the
aorta, often without any particular hemodynamic impact. Embolization into the left ventricle is more serious, as surgery is the only means
of removing the valve. The anesthesia team
should be actively involved in conversations
with the heart team about potential cardiopulmonary bypass and open techniques to retrieve
or repair the misplaced valve.

Acute Aortic Dissection

Rarely, deployment of a transcatheter valve
results in an intimal injury near the sino-tubular
junction.17 These injuries may cause acute aortic
dissection, which presents with unexpected
chest pain. If the patient is in a hybrid operating room, TEE or angiography may confirm it. If
the patient is in the recovery area, an emergent
computed tomographic angiography would be
diagnostic. Control of blood pressure within
a normal range would be the primary goal
of the anesthesia team, in these cases, and
preparations for emergency surgery would be
expected. Consideration should be given to
the placement of hemodynamic monitoring
catheters, recognizing that right axillary artery
cannulation for cardiopulmonary bypass may
be necessary.

Conclusion

When considering complications of TAVR, the
anesthesia team should be prepared for both
common and unusual events. TAVR is generally
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safe, even with a minimalist approach, performed in the heart catheterization laboratory.
The anesthesiologist is sometimes called upon
to treat emergent conditions in the perioperative period of TAVR cases; in this regard, “forewarned is forearmed”.
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